NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Orizuru Therapeutics, Inc.

Orizuru Therapeutics, Inc.

Private
KyotoHealthcare & Life Scienceshttps://orizuru-therapeutics.com/

Last Round

Series B

Feb 29, 2024

Total Funding Raised

$76.62M

Company Overview

Orizuru Therapeutics, Inc. is a biotechnology company that develops regenerative medical products through cell therapy and provides services to support drug discovery research using induced pluripotent stem cell (iPSC) technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

induced pluripotent stem celliPSCregenerative medicinecell therapystem cell therapycardiomyocyte therapypancreatic islet cellsdrug discoverybiotechcell transplantationbiotech research servicesclinical-stage biotechlab servicescell manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Orizuru Therapeutics, Inc. Comparables

Compare Orizuru Therapeutics, Inc. with similar companies based on industry and business-model similarity.

Orizuru Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
iPS Bio, Inc.
82%
Rege Nephro Co., Ltd.
82%
iHeart Japan Corporation
79%

Orizuru Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 29, 2024
Series AAug 10, 2021
SeedAug 10, 2021

Key People

Founding team and executive leadership

Kenji Nonaka

Chief Executive Officer

Executive Team

Yu Yoshimura

Chief Financial Officer

Executive Team

Orizuru Therapeutics, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 29, 2024

    $22M round led by Japan Growth Capital Investment Corporation.

  • Aug 10, 2021

    $55M round with MUFG Bank and SMBC Venture Capital.

Orizuru Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Orizuru Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Orizuru Therapeutics, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersKyoto
Employee Range21
Year Founded2021
Last FundingFeb 29, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.